Roflumilast treatment during forced abstinence reduces relapse to methamphetamine seeking and taking.
| Autor: | Baek JJ; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Kline H; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Deveau CM; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Yamamoto BK; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Addiction biology [Addict Biol] 2022 Jan; Vol. 27 (1), pp. e13082. Date of Electronic Publication: 2021 Aug 07. |
| DOI: | 10.1111/adb.13082 |
| Abstrakt: | Methamphetamine (METH) is a psychostimulant with high abuse potential. Currently, there are no pharmacological treatments specific for METH abuse or stimulant use disorder generally. Although phosphodiesterase inhibitors have shown some promise, current animal models have not examined their use in abstinence from stimulant abuse. We employed a METH self-administration model in the rat followed by a forced abstinence period during which roflumilast, a phosphodiesterase 4 inhibitor, was administered. A detailed behavioral analysis of chronic treatment with roflumilast during 7 days of forced abstinence showed that roflumilast reduced METH seeking and METH taking upon subsequent relapse test. Roflumilast treatment during 7 days of forced abstinence did not affect sucrose seeking and sucrose taking behaviors. These data suggest that roflumilast may be a treatment for METH use disorder that is effective when administered only during abstinence. (© 2021 Society for the Study of Addiction.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|